Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21.951
Filtrar
1.
Recurso na Internet em Português | LIS - Localizador de Informação em Saúde | ID: lis-47920

RESUMO

O Ministério da Saúde anunciou, nesta quinta-feira (8), a previsão de 140 milhões de doses da vacina para Covid-19. A expectativa é que a população tenha acesso a vacina aos insumos a partir de janeiro de 2021, após aprovação pela Agência Nacional de Vigilância Sanitária (Anvisa).


Assuntos
Infecções por Coronavirus , Vacinas/imunologia
4.
Dtsch Med Wochenschr ; 145(20): 1464-1468, 2020 10.
Artigo em Alemão | MEDLINE | ID: mdl-33022727

RESUMO

Vaccination practices in Germany are driven by scientific developments and a complex regulatory environment. Some important developments in 2019/20 are described here: Work-related vaccination recommendations for measles, rubella, and chickenpox have been streamlined and expanded. In addition, measles vaccination or documentation of immunity is now mandatory for employment at and attendance of many institutions, specifically including day care centers and schools. Owing to the shift of pneumococcal serotypes since the introduction of conjugate vaccines the US ACIP no longer recommends these for the routine administration to healthy persons of older age. Reduced series of 2 or even 1 dose of an HPV vaccine may be sufficient, however definitive RCT data are not yet available. After years of development and clinical studies the first vaccine against Ebolavirus disease has been licensed by EMA in November and by FDA in December 2019. More than 150 SARS-CoV-2 vaccine candidates are being developed with massive financial support, several phase 1/2 trials have started. A licensed vaccine may actually be available in 2021 and thus dramatically faster compared to any other modern vaccine development.


Assuntos
Vacinação em Massa , Vacinas , Adulto , Ensaios Clínicos como Assunto , Infecções por Coronavirus/prevenção & controle , Alemanha , Humanos , Esquemas de Imunização , Vacinas Virais
5.
Recurso na Internet em Português | LIS - Localizador de Informação em Saúde | ID: lis-47900

RESUMO

O Ministério da Saúde aderiu ao Instrumento de Acesso Global de Vacinas Covid-19 (Covax Facility). A adesão irá permitir que o Brasil tenha, entre suas opções, pelo menos mais nove vacinas em desenvolvimento. Desta forma, assim que concluída uma vacina de comprovada eficácia e segurança, o país poderá imunizar os grupos de risco da doença a partir de 2021


Assuntos
Vacinas , Infecções por Coronavirus
6.
Recurso na Internet em Português | LIS - Localizador de Informação em Saúde | ID: lis-47901

RESUMO

Os países não devem esperar que uma vacina contra a COVID-19 seja desenvolvida para começar a planejar e se preparar para sua chegada, afirmou nesta quarta-feira (23) a diretora da Organização Pan-Americana da Saúde (OPAS), Carissa F Etienne. Enquanto isso, também devem continuar com outras medidas de saúde pública recomendadas para conter o vírus.


Assuntos
Infecções por Coronavirus , Vacinas
7.
Recurso na Internet em Português | LIS - Localizador de Informação em Saúde | ID: lis-47873

RESUMO

Os testes da vacina contra a Covid-19, desenvolvida pela Universidade de Oxford, foram suspensos após suspeita de reação adversa em um voluntário no Reino Unido. Ao ser comunicado oficialmente pelo laboratório AstraZeneca, o Ministério da Saúde se posicionou – reforçando o compromisso em garantir à população brasileira acesso a uma vacina segura e eficaz


Assuntos
Infecções por Coronavirus , Vacinas/isolamento & purificação
8.
Recurso na Internet em Português | LIS - Localizador de Informação em Saúde | ID: lis-47844

RESUMO

A diretora da Organização Pan-Americana da Saúde (OPAS), Carissa F. Etienne, pediu nesta quinta-feira (27) ao bloco PROSUL de presidentes sul-americanos para trabalharem juntos no acesso às vacinas contra a COVID-19.


Assuntos
Infecções por Coronavirus , Vacinas , América do Sul
9.
Lima; Perú. Ministerio de Salud; 20200900. 27 p.
Monografia em Espanhol | LILACS, MINSAPERU | ID: biblio-1118679

RESUMO

El documento contiene los criterios de calidad, seguridad y eficiencia de vacunas en investigación, destinadas a la prevención de enfermedades infecciosas.


Assuntos
Pesquisa , Segurança , Vacinas , Saúde , Doenças Transmissíveis , Eficiência , Prevenção de Doenças , Normas Técnicas
11.
Ann Clin Microbiol Antimicrob ; 19(1): 40, 2020 Sep 02.
Artigo em Inglês | MEDLINE | ID: mdl-32878641

RESUMO

A novel coronavirus (SARS-CoV-2), causing an emerging coronavirus disease (COVID-19), first detected in Wuhan City, Hubei Province, China, which has taken a catastrophic turn with high toll rates in China and subsequently spreading across the globe. The rapid spread of this virus to more than 210 countries while affecting more than 25 million people and causing more than 843,000 human deaths, it has resulted in a pandemic situation in the world. The SARS-CoV-2 virus belongs to the genus Betacoronavirus, like MERS-CoV and SARS-CoV, all of which originated in bats. It is highly contagious, causing symptoms like fever, dyspnea, asthenia and pneumonia, thrombocytopenia, and the severely infected patients succumb to the disease. Coronaviruses (CoVs) among all known RNA viruses have the largest genomes ranging from 26 to 32 kb in length. Extensive research has been conducted to understand the molecular basis of the SARS-CoV-2 infection and evolution, develop effective therapeutics, antiviral drugs, and vaccines, and to design rapid and confirmatory viral diagnostics as well as adopt appropriate prevention and control strategies. To date, August 30, 2020, no effective, proven therapeutic antibodies or specific drugs, and vaccines have turned up. In this review article, we describe the underlying molecular organization and phylogenetic analysis of the coronaviruses, including the SARS-CoV-2, and recent advances in diagnosis and vaccine development in brief and focusing mainly on developing potential therapeutic options that can be explored to manage this pandemic virus infection, which would help in valid countering of COVID-19.


Assuntos
Antivirais/uso terapêutico , Infecções por Coronavirus/tratamento farmacológico , Infecções por Coronavirus/prevenção & controle , Coronavirus/imunologia , Pandemias/prevenção & controle , Síndrome Respiratória Aguda Grave/tratamento farmacológico , Vacinas/uso terapêutico , Betacoronavirus , China/epidemiologia , Infecções por Coronavirus/epidemiologia , Humanos , Síndrome Respiratória Aguda Grave/epidemiologia
12.
Lancet ; 396(10255): 877, 2020 09 26.
Artigo em Inglês | MEDLINE | ID: mdl-32919523
13.
Lancet ; 396(10255): 898-908, 2020 09 26.
Artigo em Inglês | MEDLINE | ID: mdl-32919524

RESUMO

BACKGROUND: There is growing evidence of vaccine delays or refusals due to a lack of trust in the importance, safety, or effectiveness of vaccines, alongside persisting access issues. Although immunisation coverage is reported administratively across the world, no similarly robust monitoring system exists for vaccine confidence. In this study, vaccine confidence was mapped across 149 countries between 2015 and 2019. METHODS: In this large-scale retrospective data-driven analysis, we examined global trends in vaccine confidence using data from 290 surveys done between September, 2015, and December, 2019, across 149 countries, and including 284 381 individuals. We used a Bayesian multinomial logit Gaussian process model to produce estimates of public perceptions towards the safety, importance, and effectiveness of vaccines. Associations between vaccine uptake and a large range of putative drivers of uptake, including vaccine confidence, socioeconomic status, and sources of trust, were determined using univariate Bayesian logistic regressions. Gibbs sampling was used for Bayesian model inference, with 95% Bayesian highest posterior density intervals used to capture uncertainty. FINDINGS: Between November, 2015, and December, 2019, we estimate that confidence in the importance, safety, and effectiveness of vaccines fell in Afghanistan, Indonesia, Pakistan, the Philippines, and South Korea. We found significant increases in respondents strongly disagreeing that vaccines are safe between 2015 and 2019 in six countries: Afghanistan, Azerbaijan, Indonesia, Nigeria, Pakistan, and Serbia. We find signs that confidence has improved between 2018 and 2019 in some EU member states, including Finland, France, Ireland, and Italy, with recent losses detected in Poland. Confidence in the importance of vaccines (rather than in their safety or effectiveness) had the strongest univariate association with vaccine uptake compared with other determinants considered. When a link was found between individuals' religious beliefs and uptake, findings indicated that minority religious groups tended to have lower probabilities of uptake. INTERPRETATION: To our knowledge, this is the largest study of global vaccine confidence to date, allowing for cross-country comparisons and changes over time. Our findings highlight the importance of regular monitoring to detect emerging trends to prompt interventions to build and sustain vaccine confidence. FUNDING: European Commission, Wellcome, and Engineering and Physical Sciences Research Council.


Assuntos
Saúde Global , Vacinação em Massa/psicologia , Opinião Pública , Confiança , Vacinas , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Vacinação em Massa/efeitos adversos , Estudos Retrospectivos , Vacinas/efeitos adversos
14.
Lancet ; 396(10255): 870-871, 2020 09 26.
Artigo em Inglês | MEDLINE | ID: mdl-32919522
15.
Vaccine ; 38(44): 6922-6929, 2020 10 14.
Artigo em Inglês | MEDLINE | ID: mdl-32893036

RESUMO

INTRODUCTION: Despite historical exclusion, there has been recent recognition of the need to address the health of pregnant women in research on vaccines against emerging pathogens. However, pregnant women's views and decision-making processes about vaccine research participation during infectious disease outbreaks remain underexplored. This study aims to examine women's decision-making processes around vaccine research participation during infectious disease outbreaks. METHODS: We conducted qualitative semi-structured in-depth interviews with pregnant and recently pregnant women (n = 13), eliciting their views on four hypothetical Zika Virus vaccine research scenarios and probing their decision-making processes around participation. After recorded interviews were transcribed, thematic analysis was conducted based on a priori and emergent themes. RESULTS: Most women interviewed were accepting of vaccine research scenarios. Three broad themes-evidence, risk, and trust-characterized women's decision-making processes. Women varied in how different types and levels of evidence impacted their considerations, which risks were most salient to their decision-making processes, and from whom they trusted recommendations about vaccine research participation. Exemplary quotes from each theme are presented, and lessons for vaccine development during the current COVID-19 pandemic and future outbreaks are discussed. CONCLUSION: Some pregnant women are accepting of participation in vaccine research during infectious disease outbreaks. Incorporating their priorities into trial design may facilitate their participation and generation of evidence for this important population.


Assuntos
Ensaios Clínicos como Assunto , Tomada de Decisões , Aceitação pelo Paciente de Cuidados de Saúde/psicologia , Gestantes/psicologia , Infecção por Zika virus/prevenção & controle , Adulto , Feminino , Humanos , Entrevistas como Assunto , Gravidez , Complicações Infecciosas na Gravidez/prevenção & controle , Medição de Risco , Vacinação , Vacinas , Vacinas Virais
16.
J Prim Care Community Health ; 11: 2150132720963634, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32996368

RESUMO

BACKGROUND: In the face of the current time-sensitive COVID-19 pandemic, the limited capacity of healthcare systems resulted in an emerging need to develop newer methods to control the spread of the pandemic. Artificial Intelligence (AI), and Machine Learning (ML) have a vast potential to exponentially optimize health care research. The use of AI-driven tools in LMIC can help in eradicating health inequalities and decrease the burden on health systems. METHODS: The literature search for this Scoping review was conducted through the PubMed database using keywords: COVID-19, Artificial Intelligence (AI), Machine Learning (ML), and Low Middle-Income Countries (LMIC). Forty-three articles were identified and screened for eligibility and 13 were included in the final review. All the items of this Scoping review are reported using guidelines for PRISMA extension for scoping reviews (PRISMA-ScR). RESULTS: Results were synthesized and reported under 4 themes. (a) The need of AI during this pandemic: AI can assist to increase the speed and accuracy of identification of cases and through data mining to deal with the health crisis efficiently, (b) Utility of AI in COVID-19 screening, contact tracing, and diagnosis: Efficacy for virus detection can a be increased by deploying the smart city data network using terminal tracking system along-with prediction of future outbreaks, (c) Use of AI in COVID-19 patient monitoring and drug development: A Deep learning system provides valuable information regarding protein structures associated with COVID-19 which could be utilized for vaccine formulation, and (d) AI beyond COVID-19 and opportunities for Low-Middle Income Countries (LMIC): There is a lack of financial, material, and human resources in LMIC, AI can minimize the workload on human labor and help in analyzing vast medical data, potentiating predictive and preventive healthcare. CONCLUSION: AI-based tools can be a game-changer for diagnosis, treatment, and management of COVID-19 patients with the potential to reshape the future of healthcare in LMIC.


Assuntos
Inteligência Artificial , Infecções por Coronavirus , Assistência à Saúde , Países em Desenvolvimento , Pandemias , Pneumonia Viral , Pesquisa , Betacoronavirus , Busca de Comunicante , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/terapia , Infecções por Coronavirus/virologia , Mineração de Dados , Desenvolvimento de Medicamentos , Humanos , Aprendizado de Máquina , Programas de Rastreamento , Pneumonia Viral/diagnóstico , Pneumonia Viral/epidemiologia , Pneumonia Viral/terapia , Pneumonia Viral/virologia , Pobreza , Vacinas
18.
Zhonghua Yu Fang Yi Xue Za Zhi ; 54(9): 915-917, 2020 Sep 06.
Artigo em Chinês | MEDLINE | ID: mdl-32907278

RESUMO

Development of an effective vaccine requires a long and complicated process. Preclinical studies and phase Ⅰ, Ⅱ, Ⅲ clinical trials mainly focused on the assessment of the vaccine's safety (tolerability), immunogenicity and efficacy before license. After license, it is necessary to further evaluate the actual effectiveness and safety in the general population through phase Ⅳ clinical trials and optimize the immunization strategies with the disease's epidemiology data. In this special issue, published several articles, which reported the main results of pre-license clinical trials and post-marketing evaluation of various vaccines, it was extremely useful to support vaccine licensing and market use. We encourage the continuous clinical studies and post-marketing evaluation of vaccines, including the novel corona virus-19 vaccines, to provide technical support for the population use, under the situation of COVID-19 pandemic.


Assuntos
Ensaios Clínicos como Assunto/organização & administração , Imunização/métodos , Vacinas , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/prevenção & controle , Humanos , Pandemias/prevenção & controle , Pneumonia Viral/epidemiologia , Pneumonia Viral/prevenção & controle , Vacinas Virais
19.
Indian J Pediatr ; 87(10): 810-816, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32880819

RESUMO

The pandemic declaration of Covid-19 disease by World Health Organization (WHO) and subsequent widespread morbidities and mortalities in almost all countries of the world led to the research and development to find out a vaccine against SARS-CoV2 virus. Normally any new vaccine development takes 10-15 y time but the search for vaccine against SARS-CoV2 is going on at a very fast pace resulting in almost breakthrough in vaccine development by several research institutions and vaccine manufacturers. In pandemic situation, however, the entire process of vaccine development including clinical trials gets shortened and may be fast tracked to 15-18 mo time. It is expected that there shall be simultaneous marketing of several vaccines by the beginning of 2021. There are more than 164 candidate vaccines which are in the process of development and among them 24 vaccines are in advanced stages of development. This review aims at highlighting the present stages of development of vaccines and discussing the challenges that may be faced with these novel vaccines.


Assuntos
Betacoronavirus/imunologia , Infecções por Coronavirus/prevenção & controle , Pandemias/prevenção & controle , Pneumonia Viral/prevenção & controle , Vacinas Virais/imunologia , Pesquisa Biomédica , Infecções por Coronavirus/imunologia , Infecções por Coronavirus/virologia , Desenvolvimento de Medicamentos , Humanos , Pneumonia Viral/imunologia , Pneumonia Viral/virologia , Vacinas , Vacinas Virais/química , Organização Mundial da Saúde
20.
Ig Sanita Pubbl ; 76(2): 143-151, 2020.
Artigo em Italiano | MEDLINE | ID: mdl-32877397

RESUMO

The development of a vaccine, particularly one that can help against the recent pandemic, is a topic that has recently attracted public opinion. More than ninety vaccines are currently being developed against Sars-Cov2 by universities and companies around the world. They are protein-based vaccines, viral vector vaccines, DNA or RNA vaccines and inactivated or attenuated viral vaccines. The development of a vaccine starts from the identification and characterization of the microorganism that causes the disease. The second step is the preclinical phase. Then, there is the phase of clinical experimentation, which allows to study the posology, efficacy and safety of the vaccine, on an increasingly larger sample. In the European Union, vaccines are authorized through two procedures (EU and national) based on the quality, safety and efficacy requirements defined by the European and international guidelines. Timing of realization, authorization and marketing of new vaccines can be shortened in cases of particular need, through an accelerated evaluation known as "Priority Medicines". In this period, it is crucial not to neglect current vaccinations. In fact, during the pandemic period, many countries postponed vaccination campaigns against many vaccine-preventable diseases, causing a marked decrease in routine immunizations in childhood.


Assuntos
Aprovação de Drogas , Vigilância de Produtos Comercializados , Vacinas , Humanos , Vacinação , Vacinas/administração & dosagem , Vacinas Atenuadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA